title: Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
authors.affiliation: Histopathology, Royal Surrey County Hospital, Egerton Road, Guildford, Surrey GU2 7XX, UK. silvana.dipalma@royalssurrey.nhs.uk
authors.forename: S
authors.initials: S
authors.lastname: Di Palma
authors.forename: N
authors.initials: N
authors.lastname: Collins
authors.forename: C
authors.initials: C
authors.lastname: Faulkes
authors.forename: B
authors.initials: B
authors.lastname: Ping
authors.forename: G
authors.initials: G
authors.lastname: Ferns
authors.forename: B
authors.initials: B
authors.lastname: Haagsma
authors.forename: G
authors.initials: G
authors.lastname: Layer
authors.forename: M W
authors.initials: MW
authors.lastname: Kissin
authors.forename: M G
authors.initials: MG
authors.lastname: Cook
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D002863:Chromogenic Compounds; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods; D018579:Patient Selection; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D002863:Chromogenic Compounds; D000068878:Trastuzumab